China’s Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced plans to establish a new sterile filling line for prefilled syringes (PFS) at its facility in Leverkusen, Germany. This move is set to enhance the company’s drug product (DP) capabilities in the region, optimizing the facility’s manufacturing layout for more efficient multi-product CRDMO services.
Expansion Details and Efficiency Gains
The expansion will allow the processing of syringes in multiple sizes, including 1 ml, 2.25 ml, and 3 ml, on the new line. The line is designed to operate at a filling rate of up to 400 syringes per minute, with an annual production capacity of at least 17 million syringes. This addition to the existing sterile filling and freeze-drying line, which has an annual capacity of approximately ten million doses, will enable WuXi Biologics to flexibly meet the diversified needs of its global customers.
Construction and Compliance Timeline
Construction of the new sterile filling line is set to commence shortly, with the aim of achieving Good Manufacturing Practice (GMP) compliance by 2026. This timeline underscores WuXi Biologics’ commitment to enhancing its manufacturing capabilities in line with international standards, ensuring the highest quality and safety of its drug products.-Fineline Info & Tech
Leave a Reply